O. Michael Colvin, M.D., an AACR member since 1975, died on March 16 at the age of 76. He was professor emeritus of medicine at Duke University in Durham, N.C.

Born on June 15, 1936, in Princeton, Ind., Colvin graduated from Indiana University in 1957 and received his medical degree from Washington University School of Medicine in St. Louis, Mo., in 1961. He spent two years as a fellow at the National Cancer Institute before continuing his career at Johns Hopkins University in Baltimore, Md., where he was professor of medicine and pharmacology, director of the Division of Pharmacology and Experimental Therapeutics for the oncology center and research director of the oncology center. He also served as associate dean for research for Johns Hopkins University School of Medicine.

Colvin became director of the Duke University Comprehensive Cancer Center in 1995, and was named the William W. Shingleton professor of cancer research and professor of pharmacology and cancer biology. He was known for his work establishing the mechanism of action of several drugs, and was one of the first researchers to use high-dose cyclophosphamide to treat solid tumors.

He served the AACR in numerous capacities, including as a member of the board of directors (1997-2000) and as founding deputy editor (2001-2005) and special assistant to the editor-in-chief (2006-2012) of Molecular Cancer Therapeutics. He was also a member of the Bruce F. Cain Memorial Award Committee, the Prevention Working Group Committee, the Publications Committee and the Mechanisms of Drug Action Committee. Additionally, he served as a mentor in the Scientist↔Survivor program.

Colvin also served on the advisory board of the National Institute of Health Center for Scientific Review and received several honors throughout his career. He was an elected member of the Association of American Physicians, Phi Beta Kappa, Alpha Omega Alpha, and received the R. Wayne Rundles, M.D., Award for Excellence in Cancer Research in 2003.